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We investigated the effect of efavirenz on the activities of CYP1A2, CYP2A6, 
xanthine oxidase (XO) and N-acetyltransferase 2 (NAT2), using caffeine as a probe. 
A single 150 mg oral dose of caffeine was administered to healthy volunteers (n = 
58) on two separate occasions; with a single 600 mg oral dose of efavirenz; and after 
treatment with 600 mg/day efavirenz for 17 days. Caffeine and its metabolites in 
plasma and urine were quantified using liquid chromatography/tandem-mass 
spectrometry. DNA was genotyped for CYP2B6*4 (785A>G), CYP2B6*9 (516G>T), 
and CYP2B6*18 (983T>C) alleles using TaqMan assays. Relative to single-dose 
efavirenz treatment, multiple-doses of efavirenz decreased CYP1A2 (by 38%) and 
increased CYP2A6 (by 85%) activities (P < 0.05); XO and NAT2 activities were 
unaffected. CYP2B6*6*6 genotype was associated with lower CYP1A2 activity 
following both single and multiple doses of efavirenz. No similar association was 
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hepatic CYP1A2 and suggesting chronic efavirenz exposure likely enhances the 
elimination of CYP2A6 substrates. This is also the first to report the extent of 




The non-nucleoside HIV-1 reverse transcriptase inhibitor efavirenz, in 
combination with two nucleoside/nucleotide reverse transcriptase inhibitors, has 
been the preferred first-line regimen for over 15 years for treatment naive HIV 
infected adults (1) and children (2). Although regimens containing efavirenz are 
considered alternative therapy since 2015 due to the increased effectiveness of 
newer agents such as integrase inhibitors (3), the World Health Organization 
continues to recommend efavirenz-based therapies as cost-effective and convenient 
first-line therapy in resource-limited countries with pandemic HIV (4). However, the 
use of efavirenz is associated with numerous and often unpredictable 
pharmacokinetic drug-drug interactions (DDIs) (5). These DDIs are of major clinical 
concerns as they potentially increase the risk for loss of efficacy or adverse effects of 
those drugs co-administered with efavirenz. Thus, understanding the mechanisms of 
these DDIs is crucial to predict and manage them. 
Most efavirenz mediated DDIs can be explained by efavirenz’s ability to 
induce drug disposition genes via activation of the constitutive androstane receptor 
(CAR) (6) and pregnane X receptor (PXR) (7), nuclear receptors that regulate the 
transcription of drug-metabolizing enzymes and transporters (8). As a result, chronic 
administration of efavirenz increases its own elimination (“autoinduction” of 
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enzymes including CYP2B6, CYP2C19 and CYP3A (10),(11),(12). However, not all 
DDIs with efavirenz are due to induction of drug disposition genes. Our in vitro data 
show that efavirenz directly inhibits certain enzymes at therapeutically relevant 
concentrations (e.g., CYP2B6, CYP2C8, CYP2C19 and CYP2C9) (13), with 
reduction in the elimination of CYP2C8 and CYP2C9 substrates in vivo (14),(15) and 
efavirenz being a mixed inhibitor/inducer of CYP2B6(16) and CYP2C19(11). The 
potential in vivo effect of efavirenz on the activity of other drug metabolizing 
enzymes, such as CYP1A2, CYP2A6, xanthine oxidase (XO) and N-
acetyltransferase 2 (NAT 2), is not fully investigated. In HIV/TB-co-infected patients, 
model predicted exposure of isoniazid exposure was marginally reduced by 
efavirenz (by 29%) in those who are fast acetylators, but no effect was observed in 
slow acetylators (17). However, these patients were receiving multiple medications, 
making it difficult to attribute the observed effect to efavirenz alone. Using human 
liver microsomal (HLMs) preparations and/or expressed enzymes, we have shown 
that efavirenz does not inhibit/inactivate the activities of CYP1A2, CYP2A6 (13). 
While HLMs are important in vitro experimental tools to estimate the estimation and 
prediction of inhibition DDI potential of a drug candidate, this approach would not be 
appropriate to test the effect of efavirenz on gene expression (e.g., due to enzyme 
induction). Appropriate in vitro models (e.g., cell lines or human hepatocytes) or in 
vivo studies using probe substrates are required to exclude the potential effect of 
efavirenz on CYP1A2 and CYP2A6.  
Efavirenz is mainly metabolized by hepatic CYP2B6 (18). Two gene variants 
(CYP2B6*6 and CYP2B6*18) produce higher efavirenz exposure after standard 
dosing in HIV patients (19). The extent of efavirenz autoinduction of metabolism is 
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extent of efavirenz-mediated DDIs with such CYP3A substrates as lumefantrine (21) 
and levonogestrel (22) also depends on the variability in CYP2B6 gene expression, 
suggesting that variable efavirenz exposure to functionally relevant CYP2B6 genetic 
variants and other factors may be important determinant of the magnitude of DDIs.  
The main objectives of this study were to test whether (1) efavirenz alters the 
activity of CYP1A2 in healthy volunteers and (2) the magnitude of the alteration 
correlated with genetic variation in CYP2B6 expression. Caffeine is extensively 
metabolized in humans with at least 17 metabolites identified in the urine following 
caffeine administration (23),(24),(25). Approximately 80 to 90% of the total caffeine 
elimination in humans is mediated via hepatic CYP1A2-mediated demethylation to 
paraxanthine (26),(25) and caffeine is a well-established and validated probe drug 
for CYP1A2. The secondary objective of this study is to explore the effect of 
efavirenz on the activities of CYP2A6, xanthine oxidase (XO) and N-
acetyltransferase 2 (NAT2). CYP2A6, XO and NAT2 are involved in the formation of 
caffeine metabolites (24),(25). Although these enzymes catalyze minor metabolic 
pathways which make difficult to validate against oral clearance of caffeine, urinary 
metabolic ratios of caffeine have been widely used as convenient markers of 
CYP1A2, CYP2A6, XO and NAT2 activities in population, epidemiological and drug-
drug interactions (27),(24),(25). Activities of hepatic CYP1A2, CYP2A6, XO and 
NAT2 were profiled in healthy volunteers using plasma and urinary caffeine and 
metabolites as an in vivo probes following the administration of caffeine on two 
occasions: with a single 600 mg oral dose of efavirenz and after chronic efavirenz 
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MATERIALS AND METHODS 
Study subjects. Healthy male and female volunteers (age, 18 to 49 years old; and 
BMI, 20-32 kg/m2) were recruited to participate in this study. Potential subjects 
underwent a pre-enrollment screening examination (within a maximum of six weeks 
prior to enrollment into the study) for any medical abnormalities, which included 
physical examination, medical history and standard clinical laboratory tests. Details 
of inclusion and exclusion criteria are described in our previous publications 
(11),(28),(29),(30). During the screening, a blood sample (10 ml) was obtained from 
each subject to extract genomic DNA for genotyping purposes. The Indiana 
University (IU) Institutional Review Board approved the protocol and the study was 
conducted at the IU Clinical Research Center. All participants gave written informed 
consent. The study was registered at http://www.clinicaltrials.gov (ClinicalTrials.gov 
number NCT00668395).  
Study design. This study used a two-session sequential design to characterize 
efavirenz autoinduction, pharmacogenetics and drug interactions (Figure S1). To 
determine efavirenz-mediated changes in hepatic drug metabolizing enzyme activity, 
volunteers received a cocktail probe drugs orally with water on two occasions: 
concomitantly with a single 600 mg oral dose of efavirenz and again at the end of 17-
day treatment with 600 mg efavirenz daily. On day 1, the participants were admitted 
to the hospital ~7 AM, after an overnight fast. Following a predose blood sample, 
each participant received a single 600-mg oral dose of efavirenz (Sustiva, Bristol-
Myers Squibb, Princeton, NJ) with 240 mL water on an empty stomach. One hour 
later, a cocktail probe drugs was administered orally with water to assess potential 
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mg of midazolam syrup. Although high doses of omeprazole can induce CYP1A2 
after chronic administration, the small single dose (20 mg) used in this study is not 
expected to alter CYP1A2 activity. In fact, there is no mutual pharmacokinetic 
interaction of caffeine and omeprazole (or among the other components of the 
cocktail used here) and these probe drugs (including caffeine and omeprazole) have 
been validated for simultaneous use without fear of interaction and thus widely used 
in several CYP phenotyping cocktails. Venous blood samples (10 mL) were 
collected from an indwelling catheter 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 
hours following efavirenz administration while participants were in the hospital and at 
48, 72 and 144 hours as outpatients. All urine voided during the 24 hour after 
efavirenz administration was collected in fractions. Plasma was separated by 
centrifugation for 20 min at 3,000 rpm within an hour of collection and two 10-ml 
urine aliquots were saved from each time point after the total urine volume is 
recorded. Plasma and urine samples were immediately stored at –80oC until 
analysis. The volunteers began chronic oral efavirenz (600 mg/day) in the evening, 
from day 7 to day 23. On the morning of day 24, participants were again admitted to 
the hospital. After pre-dose blood collection, participants received their final dose of 
oral efavirenz (600 mg) and one hour later, a cocktail probe drugs was administered 
as in day 1. All other procedures and sample processing were identical to day 1. We 
present here the data that relate to efavirenz interaction with caffeine metabolism as 
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DNA genotyping.  
The CYP2B6 gene is highly polymorphic, with over 38 alleles reported to date 
(https://www.pharmvar.org/gene/CYP2B6). The CY2B6*6 allele, which consists of 
the CYP2B6*4 and CYP2B6*9 variants on the same haplotype, has functional 
relevance and occurs at high frequency across ethnically and geographically diverse 
populations (19). In addition, the CYP2B6*18 allele which does not express 
functional protein is frequent in black population (4-12%) (19). Briefly, genomic DNA 
was extracted from whole blood (QIAamp DNA Mini Kit, Qiagen, Valencia, CA). 
Polymerase chain reaction (PCR) was performed on the Quant Studio 12K Flex real-
time PCR instruments blocks for 96-well plates. CYP2B6*9, rs3745274 (516G>T, 
Q172H); CYP2B6*4, rs2279343 (785A>G, K262R); and CYP2B6*18, rs28399499 
(983T>C, I328T) were genotyped using TaqMan Assay-Reagent Allelic 
Discrimination Kits (Applied Biosystems, Foster City, CA) according to the supplier's 
instructions. Genotype groups considered for the analysis were normal metabolizer 
(*1/*1 genotype, n=36), intermediate metabolizer (*1/*6 genotype, n=15) and slow 
metabolizer (*6/*6* genotype, n=5 and *1/*18 genotype, n=1). The additional variants 
in the CYP2B6 gene and other CYP variants that were genotyped in these samples 
have been previously published (28),(30).  
Measurement of drugs and metabolites in plasma and urine. “Plasma samples 
from single and multiple doses were assayed in the same run. Similarly, urine 
samples from single and multiple doses were run together. Plasma and urine 
samples were run separately as the number of analytes tested and the methods 
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Chemicals. Caffeine (1,3,7 TMX), 1-methylxanthine (1 MX), 1-methyluric acid (1 
MU), 1,7-dimethyluric acid (1,7 DMU), 5-acetylamino-6-formylamino-3-methyluracil 
(AFMU), and 1,7-dimethylxanthine  (1,7 DMX) or paraxanthine and theobromine and 
theophylline were purchased from Sigma-Aldrich (St. Louis, MO). Efavirenz, 8-
hydroxyefavirenz, 8,14-dihydroxyefavirenz, 7-hydroxyefavirenz, and β-glucuronidase 
were purchased from Toronto Research Chemicals (North York, Ontario, Canada). 
All other chemicals and solvents were HPLC grade or the highest quality 
commercially available.  
Plasma extraction and quantification of efavirenz, caffeine and their respective 
metabolites. Plasma (250 µL) was mixed with 250 µl of 0.2M sodium acetate 
(pH=5), 12.5µL of 600mM sodium azide and 25µL of β-glucuronidase (1000U/mL) 
and incubated at 37°C for 18 hours to hydrolyze circulating glucuronide conjugates 
of efavirenz. Efavirenz-d4 (30µL of 1µg/mL) and 1 µg/ml acetaminophen were added 
as internal standards and the sample vortex mixed. Hydrochloric acid (250µL of 
0.1M) and 6 mL of ethyl acetate/hexane (50/50, v/v) was added and the sample 
mixture shaken for 10 min and then centrifuged at 3600 rpm for 10min at 0°C 
(Beckman Coulter, Schaumburg, IL). The organic layer was evaporated to dryness 
and reconstituted in 120 µL of 50% mobile phase A and 50% mobile phase B. 
Aliquot (25 µL) was injected onto the high performance liquid 
chromatography/tandem-mass spectrometry (HPLC-MS/MS) system. 
Caffeine and its metabolites were quantified on an API 3200 triple-quadrupole mass 
spectrometer (Applied Biosystem/MDS Sciex, Foster City, CA) equipped with a turbo 
ion spray source. The HPLC system consist of two LC-20AD pumps, SIL-20AHT 
UFLC auto-sampler, DGU-20A3 degasser and a CBM-20A controller (Shimadzu, 
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(250X4.6mm, 5µm particle size) column (Bellefonte, PA). Before and after each 
injection, the sampling needle was washed with acetonitrile/water (75%/25%, v/v). 
Mobile phase A [methanol : formic acid (0.1% in water; 1/99, v/v)] and mobile phase 
B [methanol : formic acid (0.1% in water; 99/1, v/v)] was pumped at 0.8 ml/min using 
a gradient elution described elsewhere (30). MS optimization was achieved via 
adjustment of both the compound- and instrument-dependent parameters for 
caffeine, theophylline, paraxanthine and acetaminophen (internal standard) in 
positive mode. The analytes were optimized at a source temperature of 400°C in 
positive mode under unit resolution for quadrupole 1 and 3, and were given a dwell 
time of 60 ms and a setting time of 700 ms. Gas pressures for all analytes, including 
the internal standards were optimized as described previously (30). Multiple 
Reaction Monitoring (MRM) at m/z of 195.12/138.12, 181.13/124.20, 181.13/124.2, 
and 152.13/110.20 for caffeine, theophylline, paraxanthine, and acetaminophen 
(internal standard), respectively, in positive mode was used. Theophylline and 
paraxanthine were chromatographically separated. Data acquisition and processing 
were performed using Analyst® software. The lower limit of quantification was 1 
ng/ml for all analytes and was linear over a wide range of therapeutically relevant 
concentrations. The intra-day and inter-day variabilities were less than 20%.  
Efavirenz, 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were 
quantified by LC/MS/MS in negative mode using efavirenz-d4 as an internal standard 
as detailed in our previous publication (30). MRMat m/z of 313.97/244.01, 
329.98/210.0, 329.98/257.89, 345.91/262.0, and 318.01/247.95 was used to 
measure first and third quadrupole (Q1/Q3) transitions for efavirenz, 8-
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(internal standard), respectively, in negative mode. Metabolites (8-and 7-
hydroxyefavirenz) were separated chromatographically. 
Urine extraction and quantification. Urine (250 µL) was spiked with 30µL of 
internal standard (nevirapine, 500ng/mL). Each sample was extracted by adding 300 
µL of acetic acid (0.1% in water) and 6mL of dichloromethane: isopropyl alcohol 
(85:15), vortex-mix for 20s, centrifuged at 3600 rpm for 5 minutes at 10°C. The 
aqueous layer was decanted by suction and the organic layer evaporated using 
speed vacuum. Residue was reconstituted in 100 µL of 99% ammonium acetate 
(20mM, pH = 4.8)/1% methanol and vortex-mix for 15 seconds. An aliquot (50µL) 
was injected onto LC/MS/MS system described above for plasma. Analytes were 
separated on a Zorbax Eclipse XDB-C8 column (4.6 x 150mm, 3.5µM, Agilent 
Technologies, Santa Clara, CA). The gradient mobile phase was pumped at a flow 
rate of 0.5 mL/min and consist of phase A [99% ammonium acetate (20mM, 
pH=3.5)/1% methanol (v/v)] and phase B [10% ammonium acetate (20mM, 
pH=3.5)/90% methanol (v/v)]. MRM at m/z 195.12/138.12 for caffeine, 181.13/124.2 
for theophylline, 181.13/124.2 for paraxanthine, 181/138 for theobromine, 166/149 
for 1-methylxanthine, 183/105 1-methyluric acid, 195/180 for 1,7-dimethyluric acid, 
225/197 for 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 152.1/110.2 for 
acetaminophen (internal standard) was used to measure first and third quadrupole 
(Q1/Q3) transitions, in positive mode. Theophylline, paraxanthine and theobromine 
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Pharmacokinetic analyses: 
Pharmacokinetic parameters were estimated using WinNonlin software (Version 
5.01; Pharsight, Mountain View, CA). Area under the plasma concentration vs. time 
curve (AUC) from time zero to the time of the last quantifiable concentration (AUC0-t) 
was estimated using the linear and logarithmic trapezoidal rule for the respective up 
and down portions of the curve. The elimination rate constant (λz) was determined by 
linear regression analysis of the terminal portion of the log concentration vs. time 
curve. The AUC (AUC0-) from zero to infinity was calculated as the sum of Ct/ λz 
and AUC0-t, where Ct was the last measured concentration. The terminal elimination 
half-life (t1/2) was calculated as the quotient of 0.693 and λz. The maximum plasma 
concentration (Cmax) and the time to Cmax (tmax) were determined by visual inspection 
of the respective individual concentration-time curves. Total clearance (CL/F) was 
calculated as the quotient of the administered dose and AUC0-. 
Calculation of metabolic ratios: 
Systemic clearance, caffeine AUC and/or plasma paraxanthine to caffeine metabolic 
ratios (MRs) 5–7 h after administration of caffeine are preferred (or accepted) and 
validated in vivo metrics of CYP1A2 activity (26). In addition, urinary metabolic ratios 
are useful markers of CYP1A2, CYP2A6, XO and NAT2 activities. Therefore, the 
following plasma and urinary caffeine MRs were calculated as indices of the 
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Plasma MRs: 
 
CYP1A2 activity = Paraxanthine concentrations (C5 hour + C7 hour)  
Caffeine concentrations (C5 hour + C7 hour)  
Where C is plasma concentrations at 5 and 7 hours post caffeine 
dosing.  
Urinary MRs: 
CYP1A2 Activity = (AFMU+ 1 MU + 1 MX)/ 1,7 DMU 
CYP2A6 Activity = 1,7 DMU/1,7 DMX 
XO Activity = (1 MU)/ (1 MX+1 MU)  
NAT2 Activity = AFMU/ (AFMU+1 MU+1 MX). 
Abbreviations: 1 MX = 1-methylxanthine; 1 MU = 1-methyluric acid; 1,7 DMU = 1,7-
dimethyluric acid; AFMU = 5-acetylamino-6-formylamino-3-methyluracil; and 1,7 
DMX = 1,7-dimethylxanthine (paraxanthine).  
Statistical analyses: 
Data are expressed as mean ± SD. Statistical analyses were performed using 
GraphPad Prism Software (La Jolla, CA, USA). Comparison of pharmacokinetic 
parameters or enzyme activity between single and multiple doses of efavirenz was 
performed using the Wilcoxon-matched paired test. For testing the association 
between CYP2B6 genotype and the activities of CYP1A2 and CYP2A6 following 
single and multiple doses of efavirenz were evaluated by nonparametric analysis of 
variance (Kruskall-Wallis test) using Dunn’s post-test for multiple comparison 
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(CYP1A2 and CYP2A6) were determined from the Spearman's Rank-Order 
Correlation (rs). Differences were judged to be due to chronic efavirenz treatment 
rather than single dose efavirenz administration when P < 0.05. 
A sample size of at least 52 subjects was calculated as sufficient to provide a 95% 
power to detect a 40% difference in CYP1A2 activity between a single efavirenz 
dose versus multiple doses of efavirenz at a two-sided alpha level of 5%. Power 
calculation for efavirenz’s effect on CYP2A6, NAT2 and XO was not performed 
apriori. However, data from a relatively large sample size were analyzed in this study 
as compared to conventional drug-drug interactions reported in the literature, which 




Sixty healthy normal volunteers were recruited and completed the entire study 
protocol. Two participants were excluded due to missing samples from one of the 
efavirenz treatment phases. Caffeine metabolic ratios were calculated from 58 
individuals. Plasma pharmacokinetic parameters were available from only 52 
volunteers after documentation of exogenous caffeine intake by six individuals during 
the study; this was an exclusion criteria.  
The demographics of the 58 participants completing the study were: 36 male 
and 22 female; median age of 28.5 years (range 18 to 50 years); body weight of 74.6 
+ 13.7 kg; and BMI of 24.6 + 3.8 kg/m2. Based on self-identification, 74 % were 
white/Caucasian and 19% were black/African-American. The remaining ~7% 
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The pharmacokinetics of caffeine and metabolite data are shown in Table 1. 
The caffeine half-life (t1/2) was prolonged (P < 0.0001) and AUC0-∞ increased (P < 
0.01) following chronic efavirenz compared to a single dose of efavirenz. 
Accordingly, chronic administration of efavirenz decreased the Cmax of paraxanthine 
(P < 0.0001), the major metabolite of caffeine. Relative to the single dose phase, 
chronic efavirenz treatment decreased CYP1A2 activity (plasma MRs) by 38 percent 
(Table 1 and Figure 1A, P < 0.0001) with marked interindividual variability (range: -
78.2% to 31.7%) (Figure 1B). Similarly, CYP1A2 activity measured by urinary MRs 
decreased 28.9% (P < 0.0001) from 5.7 to 3.6 after chronic treatment with efavirenz 
(Table 1; Figure 1C). The percent change in urine MR also varied widely among 
individuals (ranging from -65.1% to 43.2%) (Figure 1D). CYP1A2 activity measured 
by the plasma MRs correlated with CYP1A2 activity measured by urinary MRs in the 
single dose efavirenz phase (Spearman rs = 0.57; P < 0.0001) and after chronic 
efavirenz (r = 0.33, P = 0.013) and combination of both phases (single dose and 
after multiple doses of efavirenz) (rs = 0.57; P < 0.0001) [Figure S2 (A-C)]. Plasma 
caffeine MRs are the preferred phenotype marker for CYP1A2 rather than urinary 
MRs (27). Thus, only results from plasma MRs are presented as markers of CYP1A2 
subsequently.  
CYP2A6, XO and NAT-2 activities were estimated from respective caffeine 
MRs as described in the Methods section. Chronic efavirenz treatment significantly 
increased CYP2A6 activity (Table 1; Figure 2A) with marked inter-subject variability 
(range: 45.4 to 281.4%) (Figure 2B). Urinary metabolic ratios reflecting XO and 











This article is protected by copyright. All rights reserved. 
Approximately 7-fold between subject differences in efavirenz exposure was 
observed following a single dose and multiple doses of efavirenz. To test whether 
changes in CYP1A2 and CYP2A6 activities were dependent on the exposure of 
efavirenz and its metabolites, correlations between efavirenz exposure and indices 
of CYP1A2 and CYP2A6 were examined. Greater reduction in CYP1A2 activity was 
observed with higher efavirenz exposure as shown by the negatively significant 
correlation between: CYP1A2 activity and efavirenz AUC0-∞ at single dose (Pearson 
rs = - 0.32; P < 0.01) as well as efavirenz AUC0-24h after multiple doses (rs = -0.61, P 
< 0.001). The percent change in CYP1A2 was negatively correlated with efavirenz 
AUC0-24h after multiple doses (rs = -0.41, P < 0.01) (Figure S3). Efavirenz exposure at 
single dose or at steady state did not significantly correlate with urine marker of 
CYP2A6 activity (Figure S4). Exposure of efavirenz metabolites did not correlate with 
CYP1A2 or CYP2A6 activity.  
The correlation analysis suggest that the extent of reduction of CYP1A2 
activity dependent on efavirenz exposure (the higher the efavirenz exposure the 
greater reduction in CYP1A2). Genotype-phenotype data from the same subjects 
analyzed in this study and published elsewhere (30),(29) show that efavirenz 
exposure following: a single dose of efavirenz (AUC0-∞) was 2.1- and 1.8-fold higher; 
and multiple doses of efavirenz (AUC0-24) was 2.5- and 2-fold higher in CYP2B6*6/*6 
genotypes compared to CYP2B6*1/*1 and CYP2B6*1/*6 genotypes, respectively. 
Difference in efavirenz exposure between *1/*1 and *1/*6, although statistically 
different, was small. To test whether the extent of efavirenz-CYP1A2 interaction is 
dependent on CYP2B6 genotypes, data analyses was performed after stratifying by 
CYP2B6*1/*1, CYP2B6*1/*6 and CYP2B6*6/*6 genotypes. One subject with *1/*18 
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slow metabolizer. The demographics are comparable among the three genotypes 
(Table S1). CYP1A2 activity was lower for the CYP2B6*6/*6 genotypes compared to 
*1/*1 or *1/*6 genotypes following single dose (Kruskal-Wallis test, P < 0.05; Figure 
3A) and multiple doses of efavirenz (P < 0.01; Figure 3B). Compared to the single 
dose phase, chronic efavirenz inhibited CYP1A2 activity within each genotype (P < 
0.05, (Figure 3C). The percent change in CYP1A2 activity was greater in *6/*6 
genotypes when compared with *1/*1 and *1/*6 genotypes (Kruskal-Wallis test, P < 
0.05) (Figure 3D). Similarly, caffeine AUC0-∞ was significantly higher for *6/*6 
genotype in both efavirenz treatment groups compared to *1/*1 genotype [Figure S5 
(A-B), while caffeine AUC0-∞ and CYP1A2 for the *1/*6 genotype were not different 
from the wild type *1/*1 genotype in either treatment group.  
The impact of CYP2B6 genotypes on the extent of efavirenz-mediated 
induction of CYP2A6 was also tested. CYP2A6 activity was not statistically different 
among the CYP2B6 genotypes either at single dose of efavirenz (Figure 4A) or after 
multiple doses of efavirenz (Figure 4B). Compared to the single dose phase, chronic 
efavirenz increased the urinary caffeine metabolic ratio for CYP2A6 in *1/*1 and 
*1/*6 genotypes, but not in *6/*6 genotype (Figure 4C). Although percent change in 
CYP2A6 activity was lower in *6/*6 genotypes when compared with *1/*1 and *1/*6 
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DISCUSSION 
In the present study, chronic administration of efavirenz significantly reduced 
and increased the in vivo activity of hepatic CYP1A2 and CYP2A6, respectively. The 
effect of efavirenz on CYP1A2 activity  was more pronounced in individuals with 
higher efavirenz exposure and those expressing CYP2B6*6*6 genotype, while the . 
increase in CYP2A6 activity was neither efavirenz exposure- nor CYP2B6 genotype-
dependent. Efavirenz did not significantly altered the activity XO or NAT-2. These 
data suggest that there is an increased risk for drug-drug interactions in individuals 
receiving efavirenz-based HIV therapy who are co-medicated with CYP1A2 or 
CYP2A6 substrates. Moreover, CYP2B6 genotypes associated with reduce efavirenz 
clearance may particularly alter the risk for adverse drug interactions involving 
CYP1A2.  
Efavirenz activates two nuclear receptors that regulate a range of genes 
involved in drug disposition, namely the constitutive androstane receptor (CAR, 
NR1I3) and pregnane X receptor (PXR, NR1I2) (6), (7). Accordingly, efavirenz 
treatment enhances the elimination of numerous drugs metabolized by the 
cytochromes P450 [e.g., CYP3A, CYP2B6 and CYP2C19 (10),(11),(12)]. This 
together with the fact that CYP2A6 is also transcriptionally regulated via PXR (31) 
and CAR (32) may explain our observed increase in CYP2A6 activity following 
efavirenz treatment. CYP2A6 catalyzes fully or partially the metabolism of several 
clinically used drugs (e.g., letrozole, metronidazole, efavirenz and tegafur)) (33) and 
it is anticipated that efavirenz would alter the disposition of these drugs. CYP2A6 is 
also the main metabolic pathway for nicotine elimination and contributes to the 
biotransformation of several nicotine-derived carcinogens (N’-nitrosonornicotine 
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activity has been associated with number of cigarettes smoked per day, smoking 
topography (puff volume, duration, and velocity) and smoking cessation (33). Thus, it 
is conceivable that cigarette smokers would be at increased risk for tobacco-related 
illnesses when co-prescribed efavirenz-based HIV therapy. Our data show that 
neither efavirenz exposure nor the presence of the CYP2B6 polymorphisms altered 
the magnitude of the increase in CYP2A6 activity suggesting that maximum nuclear 
receptor activation occurs at relatively low efavirenz concentrations.  
In contrast to the induction effects of efavirenz on gene expression, drug 
interactions also occur as a result of direct enzymatic inhibition by efavirenz 
(15),(34). Our findings clearly indicate that chronic doses of efavirenz significantly 
reduced CYP1A2 activity in vivo compared to CYP1A2 activity determined when 
caffeine was administered with a single dose of efavirenz. The mechanism by which 
efavirenz reduces CYP1A2 activity remains unknown. In vitro studies indicate that 
efavirenz is neither a reversible inhibitor nor a mechanism-based (i.e., time-
dependent) inactivator of of CYP1A2 activity(13). It is unlikely that efavirenz 
metabolites produce CYP1A2 inhibition because the major oxidative metabolite, 8-
hydroxyefavirenz, had no effect on CYP1A2 activity in vitro(13). Efavirenz 
hydroxylated metabolites undergo extensive conjugation mainly by 
glucuronosyltransferases. With few exceptions [e.g., glucuronides of gemfibrozil(35) 
and clopidogrel)(36)], glucuronide conjugates are relatively hydrophilic and do not 
appear to produce clinically significant drug interactions. The possibility that 
efavirenz reduces CYP1A2 activity in vivo via mechanisms other than direct 
enzymatic inhibition/inactivation cannot be excluded. However, a limitation of these 
findings is that the study design in which probe substrates including caffeine were 
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doses of efavirenz) without inclusion of caffeine alone arm (absence of efavirenz) to 
determine baseline CYP1A2 did not allow accurate determination of the true 
magnitude of efavirenz-CYP1A2 interaction.. Initially, the study was designed to 
address potential induction of drug metabolism by efavirenz.  
Of note, the CYP1A2 probe, caffeine, has low intrinsic clearance with no 
significant pre-systemic metabolism. The magnitude of the efavirenz-CYP1A2 
interaction reported here is likely an underestimate for any CYP1A2 drugs known to 
exhibit significant pre-systemic (i.e., first-pass) metabolism and low bioavailability 
(e.g., tizanidine) (37). Thus, efavirenz co-administration with CYP1A2 substrates 
possessing narrow therapeutic ranges (e.g., clozapine, olanzapine, duloxetine, 
remolten and tizanidine), would likely produce clinically significant drug interactions. 
For example, ciprofloxacin and fluvoxamine (potent inhibitors of CYP1A2) increase 
the plasma exposure of tizanidine up to 30-fold, concomitant increased toxicity (37), 
(38). Tizanidine is a α2-adrenergic agonist approved for therapy of muscle spasm 
and other conditions. It is frequently prescribed, off-label, for suppression of the 
symptoms associated with opiate withdrawal during detoxification (39),(40). Because 
some individuals with HIV infection may also suffer from and be treated for opioid 
abuse, the likelihood that tizanidine and efavirenz may be co-administered is high. 
Drug interactions with efavirenz are difficult to predict because of the marked 
interindividual variability in its plasma exposure (41). Efavirenz is mainly eliminated 
by metabolism via CYP2B6, with minor contributions from CYP2A6, CYP3A, 
CYP1A2, and UGT2B7 (18),(42),(43). Patients with variants in CYP2B6 gene (e.g., 
CYP2B6*6 and CYP2B6*18) demonstrate higher efavirenz plasma exposure after 
administration of single (30) and multiple doses(19) of efavirenz. Consistent with the 
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and published elsewhere (30),(29) show that efavirenz exposure is over 2-fold higher 
in CYP2B6*6/*6 genotypes compared to CYP2B6*1/*1 genotype. Evidence exist that 
genetic variants in the CYP2B6 gene that contributes to variable efavirenz exposure 
may dictates the magnitude of certain induction drug interactions caused by 
efavirenz. For example, efavirenz reduced lumefantrine concentrations in patients 
co-infected with HIV and malaria, resulting in poor malaria treatment response, and 
the decrease in lumefantrine concentrations was greater in those with higher 
efavirenz exposure and in CYP2B6 poor metabolizers (21). Efavirenz-based HIV 
therapy has been associated with lower levonorgestrel concentrations in women with 
the contraceptive subdermal implant (22), resulting in a risk for unintended 
pregnancy (44) particularly in CYP2B6 poor metabolizers. CYP2B6 genotypes are 
also associated with differential efavirenz autoinduction of metabolism (20). 
However, this is the first report to suggest greater reduction of CYP1A2 in carriers of 
the CYP2B6*6/*6 genotype compared to *1/*1 and *1/*6 genotypes. These data 
along with the correlation analysis showing efavirenz exposure-dependent reduction 
in CYP1A2 activity suggest that factors that increase efavirenz exposure would 
increase the risk for efavirenz-CYP1A2 interaction. The genotype-dependent effect 
may have particularly important clinical consequences in certain populations, e.g., 
this likely pose unique risks in African or African American populations as the allele 
frequencies of relevant CYP2B6 genotypes (e.g., *6 and *18) are higher in these 
populations compared to other ethnic and racial groups (45). Taken together, while 
the association of CYP2B6*6/*6 genotype on the extent of efavirenz-CYP1A2 
interaction appears plausible and anticipated, our sample size for the CYP2B6*6/*6 
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study in adequate sample size of CYP2B6 genotype subgroups may be warranted to 
validate our findings and to assess the true extent of efavirenz-CYP1A2 interaction.  
In summary, we have demonstrated that efavirenz is an inhibitor of CYP1A2 
activity and an inducer of CYP2A6 activity and is likely to alter the disposition and 
efficacy of drugs metabolized by these enzymes. The results further suggest that 
genetic and non-genetic factors will increase the risk for efavirenz mediated-drug 
interactions.  Finally, specific populations expressing higher frequencies of CYP2B6 
variants (e.g., Black and African American) may be at increased risk for efavirenz 
drug interactions. Concomitant use of CYP1A2 and CYP2A6 substrate drugs with 
efavirenz-based HIV therapy will require careful monitoring to minimize the risk of 
adverse drug effects. 
 
STUDY HIGHLIGHTS  
What Is the Current Knowledge on the Topic?  
Efavirenz-based HIV therapy is associated with complex and often unpredictable 
drug-drug interactions, potentially compromising efficacy and toxicity of 
coadministered drugs. While efavirenz cause in vivo induction and/or inhibition of 
selected drug metabolizing enzymes (e.g., CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
and CYP3A), its effect on other enzymes such as CYP1A2 and CYP2A6 is unknown. 
What Question Did This Study Address?  
This work tested the effect of efavirenz on the in vivo hepatic activities of four 
enzymes: CYP1A2, CYP2A6, xanthine oxidase (XO) and N-acetyltransferase 2 
(NAT2). The impact of efavirenz exposure and genetic variation in CYP2B6 
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disposition of a single 150 mg oral dose of caffeine was profiled in healthy volunteers 
(N = 58) as in vivo probes following a single 600 mg oral dose of efavirenz and after 
chronic efavirenz treatment for 17 days.  
What Does This Study Add To Our Knowledge?  
This is the first clinical study showing that efavirenz reduces hepatic CYP1A2 and 
suggesting chronic efavirenz exposure likely enhances the elimination of CYP2A6 
substrates. This is also the first to report the extent of efavirenz-CYP1A2 interaction 
is CYP2B6 genotype-dependent.  
How Might This Change Clinical Pharmacology or Translational Science?  
Concomitant use of CYP1A2 and CYP2A6 substrate drugs with efavirenz-based HIV 
therapy will require careful monitoring to minimize the risk of adverse drug effects. 
Moreover, CYP2B6 genotypes associated with increased efavirenz exposure may be 
particularly at increased risk for adverse drug interactions involving CYP1A2.  
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Figure 1. Relative CYP1A2 activity following single dose (SD, open circles) and 
after multiple doses of efavirenz (MD, closed circles) in healthy volunteers 
(N=58). Plasma (A) and urine (C) caffeine metabolic ratios (MRs) were calculated as 
the surrogate for relative changes in CYP1A2 activity. Ranked percent change in 
CYP1A2 activity using MRs in plasma (B) and urine (D) of 58 subjects (multiple 
doses versus a single dose of efavirenz) are shown. CYP1A2 activity following single 
dose and after multiple doses of efavirenz was compared using Wilcoxon signed-
rank test. ****P < 0.0001.  
Figure 2. Relative CYP2A6 activity following single dose (SD, open circles) and 
after multiple doses of efavirenz (MD, closed circles) in healthy volunteers 
(N=58). (A), CYP2A6 activity was calculated from urinary caffeine metabolic ratios as 
described and (B), ranked percent change in CYP2A6 activity of 58 individuals 
(multiple doses versus a single dose of efavirenz). CYP2A6 activity following single 










This article is protected by copyright. All rights reserved. 
rank test. ****P < 0.0001 (between CYP1A2 activity following SD and after MD of 
efavirenz). 
Figure 3. Relative CYP1A2 activity stratified by CYP2B6 genotypes following a 
single dose and multiple doses of efavirenz in health volunteers (N=58). 
Plasma metabolic ratio of paraxanthine to caffeine represents relative CYP1A2 
activity. (A) CYP1A2 activity following a single dose of efavirenz. (B) CYP1A2 
activity after chronic administration of efavirenz. (C) Comparison between single and 
multiple efavirenz dosing within each genotype group. (D) Represents percent 
change in CYP1A2 activity. CYP1A2 activity was compared between a SD and MDs 
of efavirenz in each genotype using Wilcoxon matched pairs test. Comparison 
among genotypes was tested using nonparametric ANOVA (Kruskal-Wallis test) with 
post-hoc Dunn’s multiple comparison test. ****P<0.0001, ***P<0.001, **P<0.01, * 
P<0.05. NS, not statistically significant (P>0.05).  
Figure 4. Relative CYP2A6 activity stratified by CYP2B6 genotypes (*1/*1, n=37; 
*1/*6, n=15; and *6/*6, n=6) following a single dose (SD) and multiple doses of 
efavirenz (MD) in health volunteers (N=58). (A) Relative CYP2A6 activity following 
a single dose of efavirenz. (B) Relative CYP2A6 activity after multiple doses of 
efavirenz. (C) Compares CYP2A6 activity between single and multiple dosing within 
each genotype group. (D) Represents percent change in CYP2A6 activity (MDs 
versus SD efavirenz). CYP2A6 activity was compared between a SD and MDs of 
efavirenz in each genotype using Wilcoxon matched pairs test. Comparison among 
genotypes was tested using nonparametric ANOVA (Kruskal-Wallis test) with post-
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Table 1. Pharmacokinetic parameters of caffeine and its main metabolite 
paraxanthine, and activities of select enzymes calculated from plasma and 
urinary metabolic ratios (MRs), following co-administration of caffeine with a 
single dose and after multiple doses of efavirenz.  
 Single Dose Multiple Dose 
Mean Percent 
Change 
Caffeine (1,3,7 TMX)    
Tmax (h) 1 (0.5 – 3) 1 (0.5 – 5)   
Cmax (ng/mL) 1,825 ± 972 1,897 ± 1,050 17.4  
AUC0-∞ (mcg/mL*h) 17.3 ± 11.6 22.7 ± 18.4** 46.2 
T1/2 (hr) 7.61 ± 8.29 8.87 ± 4.98*** 32.5 
    
Paraxanthine (1,7 MX)    
Tmax (h) 7 (1.5 – 15) 7 (1 – 15)  
Cmax (ng/mL) 504 ± 236 358 ± 208*** -24.5 
AUC0-∞ (mcg/mL*h) 10.8 ± 6.1 8.6 ± 5.8* -8.6 
T1/2 (hr) 10.85 ± 9.21 12.22 ± 7.88** 26.3 
    
Relative Change in Enzyme Activity   
Plasma MR‡  
        CYP1A2 0.52 ± 0.28 0.31 ± 0.18*** -38.1 
Urinary MR‡    
CYP1A2 5.2 ± 2.4 3.5 ± 1.3*** -28.9 
CYP2A6 0.58 ± 0.38 0.94 ± 0.59*** 85.5 
XO‡ 0.37 ± 0.16 0.37 ± 0.16 1.1 
NAT-2‡ 0.31 ± 0.21 0.32 ± 0.22 4.5 
Data are expressed as mean ± SD except Tmax which was presented as median 
(minimum – maximum). ‡MR, metabolic ratio; XO, xanthine oxidase; and NAT-2, N-
acetyltransferase 2 
*P < 0.05, **P<0.01; ***P<0.0001, Wilcoxon-matched pairs test (single dose versus 
multiple doses of efavirenz).  
Tmax, time to maximum concentration; Cmax, Maximum concentration; AUC, area 
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